RAMM Pharma Corp. RAMM
CNSX
| 07/31/2026 | 04/30/2026 | 01/31/2026 | 10/31/2025 | 07/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -66.21% | -53.45% | -42.42% | -24.89% | -17.66% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -66.21% | -53.45% | -42.42% | -24.89% | -17.66% |
| Cost of Revenue | -81.90% | -54.56% | -32.63% | -5.07% | -28.58% |
| Gross Profit | -16.11% | -51.61% | -57.16% | -53.59% | 60.80% |
| SG&A Expenses | -36.12% | -41.65% | -49.12% | -47.63% | 4.39% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -35.13% | -37.34% | -35.69% | -34.79% | -12.26% |
| Total Operating Expenses | -48.35% | -44.59% | -45.46% | -38.77% | -7.25% |
| Operating Income | 38.69% | 39.42% | 47.14% | 46.14% | 0.44% |
| Income Before Tax | 32.26% | 37.15% | 44.97% | 47.19% | -47.71% |
| Income Tax Expenses | -15.38% | -15.38% | 229.53% | 84.75% | 28.17% |
| Earnings from Continuing Operations | 32.25% | 37.13% | 44.03% | 47.12% | -47.68% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 32.25% | 37.13% | 44.03% | 47.12% | -47.68% |
| EBIT | 38.69% | 39.42% | 47.14% | 46.14% | 0.44% |
| EBITDA | 38.77% | 38.73% | 48.52% | 48.51% | -7.30% |
| EPS Basic | 32.18% | 37.04% | 43.99% | 47.14% | -47.45% |
| Normalized Basic EPS | 23.40% | 33.73% | 39.53% | 41.90% | 13.60% |
| EPS Diluted | 32.18% | 37.04% | 43.99% | 47.14% | -47.45% |
| Normalized Diluted EPS | 23.40% | 33.73% | 39.53% | 41.90% | 13.60% |
| Average Basic Shares Outstanding | 0.00% | 0.00% | 0.00% | 0.00% | 0.01% |
| Average Diluted Shares Outstanding | 0.00% | 0.00% | 0.00% | 0.00% | 0.01% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |